The increase in quarterly revenues continues to strengthen Mesoblast's balance sheet after the Company announced it entered into a US$125 million facility with its largest shareholder which ...

SCD gene therapy approaches using CRISPR, gene therapy, and base editing show different stem cell outcomes in a mouse study.

Some parts of our bodies bounce back from injury in fairly short order. The outer protective layer of the eye—called the ...

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent research, a team led by Dr. Armin Rehm presents an improved immunotherapy that ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

Michael Wang, MD, highlights several notable abstracts from ASH 2025 that collectively underscore continued progress in ...

Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation AwardExpands iNKT platform into ...

The California Institute for Regenerative Medicine (CIRM) has awarded $7.4 million to support a University of California San Diego team developing a first-of-its-kind stem cell-based gene therapy for ...

Researchers have unlocked a way to grow the immune system’s “conductors” from stem cells, bringing ready-made cancer-fighting therapies a big step closer. For the first time, scientists at the Univers ...